Brooks Laboratories Limited (BROOKS.NS)
INR 132.55
(7.07%)
INR 132.55
(7.07%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 96.1 Million INR | -14.97% |
| 2022 | 113.03 Million INR | -58.93% |
| 2021 | 275.22 Million INR | 16.61% |
| 2020 | 236.03 Million INR | 71.35% |
| 2019 | 137.74 Million INR | 37.02% |
| 2018 | 100.53 Million INR | -11.88% |
| 2017 | 114.09 Million INR | 48.19% |
| 2016 | 76.99 Million INR | 15.1% |
| 2015 | 66.89 Million INR | -11.21% |
| 2014 | 75.33 Million INR | 24.97% |
| 2013 | 60.28 Million INR | 21.0% |
| 2012 | 49.82 Million INR | -3.44% |
| 2011 | 51.6 Million INR | -6.21% |
| 2010 | 55.01 Million INR | 16.42% |
| 2009 | 47.25 Million INR | 36.15% |
| 2008 | 34.7 Million INR | -26.12% |
| 2007 | 46.98 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 102.4 Million INR | 0.0% |
| 2023 FY | 96.1 Million INR | -14.97% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 96.1 Million INR | 0.0% |
| 2022 Q2 | 218.9 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 113.03 Million INR | -58.93% |
| 2022 Q4 | 113.03 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 FY | 275.22 Million INR | 16.61% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 275.22 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 247 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 236.03 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 296.1 Million INR | 0.0% |
| 2020 FY | 236.03 Million INR | 71.35% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 137.74 Million INR | 37.02% |
| 2019 Q2 | 100.8 Million INR | 0.0% |
| 2019 Q4 | 137.74 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 100.53 Million INR | 0.0% |
| 2018 FY | 100.53 Million INR | -11.88% |
| 2018 Q2 | 101.79 Million INR | 0.0% |
| 2017 Q2 | 72.62 Million INR | 0.0% |
| 2017 FY | 114.09 Million INR | 48.19% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 114.09 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q2 | 55.96 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 76.98 Million INR | 0.0% |
| 2016 FY | 76.99 Million INR | 15.1% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 66.89 Million INR | -11.21% |
| 2015 Q4 | 66.89 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 128.7 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 92.33 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 75.33 Million INR | 24.97% |
| 2014 Q4 | 75.33 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 60.28 Million INR | 21.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 60.28 Million INR | 0.0% |
| 2013 Q2 | 47.7 Million INR | 0.0% |
| 2012 FY | 49.82 Million INR | -3.44% |
| 2012 Q2 | 72.2 Million INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q4 | 49.82 Million INR | 0.0% |
| 2011 FY | 51.6 Million INR | -6.21% |
| 2011 Q4 | 51.6 Million INR | 0.0% |
| 2010 FY | 55.01 Million INR | 16.42% |
| 2009 FY | 47.25 Million INR | 36.15% |
| 2008 FY | 34.7 Million INR | -26.12% |
| 2007 FY | 46.98 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 99.415% |
| Hester Biosciences Limited | 755.81 Million INR | 87.284% |
| Aarti Drugs Limited | 4.85 Billion INR | 98.022% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 98.505% |
| Albert David Limited | 436.12 Million INR | 77.963% |
| Alembic Limited | 113.4 Million INR | 15.249% |
| Alkem Laboratories Limited | 26.61 Billion INR | 99.639% |
| Bafna Pharmaceuticals Limited | 296.41 Million INR | 67.577% |
| Bajaj HealthCare Limited | 1.44 Billion INR | 93.328% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -276.938% |
| Eris Lifesciences Limited | 1.89 Billion INR | 94.916% |
| FDC Limited | 3.88 Billion INR | 97.529% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 98.558% |
| Gufic Biosciences Limited | 2 Billion INR | 95.206% |
| Hikal Limited | 3.03 Billion INR | 96.836% |
| Ind-Swift Limited | 640.91 Million INR | 85.005% |
| Innova Captab Limited | 1.44 Billion INR | 93.327% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 97.738% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | 35.915% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 99.255% |
| Lincoln Pharmaceuticals Limited | 771.68 Million INR | 87.546% |
| Lupin Limited | 49.53 Billion INR | 99.806% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | 92.227% |
| Medico Remedies Limited | 163.37 Million INR | 41.172% |
| Morepen Laboratories Limited | 2.48 Billion INR | 96.134% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 98.645% |
| Orchid Pharma Limited | 2.64 Billion INR | 96.363% |
| Procter & Gamble Health Limited | 1.09 Billion INR | 91.192% |
| RPG Life Sciences Limited | 1.01 Billion INR | 90.484% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -140.993% |
| Sigachi Industries Limited | 707.2 Million INR | 86.41% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 97.328% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | 95.843% |
| Themis Medicare Limited | 705.74 Million INR | 86.382% |
| Unichem Laboratories Limited | 7.04 Billion INR | 98.636% |
| Vaishali Pharma Limited | 3.79 Million INR | -2431.156% |
| Wanbury Limited | 360.23 Million INR | 73.321% |
| Windlas Biotech Limited | 621.89 Million INR | 84.546% |
| ZIM Laboratories Limited | 812.62 Million INR | 88.173% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | 8.098% |
| Ipca Laboratories Limited | 24.71 Billion INR | 99.611% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 99.903% |
| Venus Remedies Limited | 1.21 Billion INR | 92.102% |
| Sakar Healthcare Limited | 277.32 Million INR | 65.344% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 99.902% |
| Divi's Laboratories Limited | 31.84 Billion INR | 99.698% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | 95.783% |
| Mankind Pharma Limited | 15.53 Billion INR | 99.381% |
| Sequent Scientific Limited | 3.46 Billion INR | 97.224% |
| Laurus Labs Limited | 18.45 Billion INR | 99.479% |
| Neuland Laboratories Limited | 3.5 Billion INR | 97.257% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 98.087% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 99.618% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 99.721% |
| Amrutanjan Health Care Limited | 289.04 Million INR | 66.75% |
| Wockhardt Limited | 6.4 Billion INR | 98.498% |
| Bal Pharma Limited | 878.11 Million INR | 89.055% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 99.849% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | 91.886% |
| Par Drugs and Chemicals Limited | 41.77 Million INR | -130.089% |
| Caplin Point Laboratories Limited | 3.63 Billion INR | 97.353% |
| Shilpa Medicare Limited | 3.44 Billion INR | 97.214% |
| Valiant Laboratories Limited | 100.15 Million INR | 4.04% |
| Ajanta Pharma Limited | 8.28 Billion INR | 98.84% |
| Aarey Drugs & Pharmaceuticals Limited | 346.75 Million INR | 72.284% |
| Granules India Limited | 13 Billion INR | 99.261% |
| Medicamen Biotech Limited | 593.75 Million INR | 83.813% |
| Syncom Formulations (India) Limited | 210.81 Million INR | 54.411% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 99.578% |
| NATCO Pharma Limited | 7 Billion INR | 98.628% |
| Suven Life Sciences Limited | 7.08 Million INR | -1256.5% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | 1.895% |
| Strides Pharma Science Limited | 11.26 Billion INR | 99.147% |
| Indoco Remedies Limited | 3.53 Billion INR | 97.278% |
| Alpa Laboratories Limited | 136.65 Million INR | 29.67% |
| Lasa Supergenerics Limited | 190.43 Million INR | 49.532% |
| Sun Pharma Advanced Research Company Limited | 14.79 Million INR | -549.73% |